Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver More >
"Subsequent analysis of CANF's CF101 data shows promise in a certain subset of patients." (5/13/15) Can-Fite BioPharma Ltd. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Reni Benjamin More >
Richard Huebner is a senior managing partner at Denver-based GVC Capital and a member of the firm's Commitment Committee, which makes the final decisions on all the banking deals. Huebner joined GVC Capital in October of 2001 in a management capacity to plan and facilitate its growth. He has been in the securities industry for nearly 30 years. His experience includes serving as general counsel for Hanifen, Imhoff Inc. from January 1984 through September 1995. While at the firm, he served in numerous positions, including executive vice president, director and member of the executive committee of Hanifen, Imhoff Holdings Inc. In 1995, Huebner became an executive vice president, director and member of the executive committee of Hanifen, Imhoff Clearing Corp., which was sold to Fiserv Inc. in December 1997. He continued in those capacities for Fiserv Correspondent Services. Huebner received a bachelor's degree in economics and business administration from Hastings College, and a juris doctorate from the University of Nebraska.
Investment Banker Dick Huebner on How to Uncover Micro-Cap Biotechs that Deliver on Promises (11/20/14) Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all. Investing in these equities requires extraordinary expertise and experience, and that is where micro-cap investment banker Richard "Dick" Huebner excels. In this interview with The Life Sciences Report, Huebner, a senior managing partner with Denver-based GVC Capital, discusses the downside and the upside of micro-cap biotech investment, and the desirable characteristics risk takers should be looking for in very small companies.
Biotech Micro Caps Offer Promise of Mighty Returns: Dick Huebner (4/25/13) Dick Huebner knows what he wants. He's looking for biotech companies that can make it very big from a near zero-base valuation. We're talking low-end micro caps that bring a lot of risk to the table, along with the opportunity for major gains. In this interview with The Life Sciences Report, GVC Capital's senior managing partner profiles three publicly traded life sciences stories that could produce generous windfalls for investors, and a private firm about to go public that promises to do the same.
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases." (6/24/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >
"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >
"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis More >